Empowering Venture Capital Associates
Danjuma Quarless, serves as an Associate Director at AbbVie Ventures, where he specializes in early-stage biotech investing and ecosystem engagement. Relocating to San Francisco in 2023, he has played a key role in reinvigorating AbbVie’s West Coast venture presence, including his involvement as a board observer for Ambagon and Light Horse. Danjuma’s career at AbbVie began in the Genomics Research Center as a computational biologist, where he spearheaded analytics for major population genomics projects including the UK Biobank and Genomics Finland. His experience expanded through strategic leadership training with rotations in search and evaluation, alliance management, and financial decision modeling. Danjuma holds a Ph.D. in Biomedical Sciences from UC San Diego and an MBA from Kellogg School of Management at Northwestern University.
In this episode of the NextGen VC podcast, hosts Mike Hostetler and Jen sit down with Danjuma Quarless from AbbVie Ventures to delve into the world of corporate venture capital. Danjuma shares insights on how corporate VCs like AbbVie differ from traditional VCs, particularly in the biotech and pharmaceutical industries. Listeners will learn about the strategic focus of AbbVie Ventures, the importance of scientific and competitive differentiation in securing investment, and the fluid communication within AbbVie’s ecosystem. Danjuma also shares his personal journey from a research scientist to a venture capitalist, offering valuable advice for those looking to break into the venture capital space. The podcast also touches on the current trends in biotech, the challenges and opportunities in various regional ecosystems, and the importance of promoting diversity within the venture capital industry. Tune in to hear about the latest innovations in biotech, the differences in investment approaches between various regions, and how AbbVie Ventures aims to build communities and support underrepresented groups in the industry.
Mike is a partner in the San Francisco (SoMa) and San Diego offices of Wilson Sonsini Goodrich & Rosati. He has provided strategic intellectual property counseling to hundreds growth enterprises in the pharmaceutical and biotechnology industries, both venture-backed and public companies. His expertise includes patent strategy, prosecution, and diligence (both buy and sell side) for venture financings, public offerings, mergers and acquisitions.
Jennifer is a partner in the Boston office of Wilson Sonsini Goodrich & Rosati. She helps innovative startups grow into successful enterprises by providing counsel to the founders, management teams and boards and by handling the legal and strategic business issues and transactions that arise at each stage. She is a member of the National Venture Capital Association (NVCA) General Counsel Advisory Board and is a frequent speaker.